Designer drugs: mechanism of action and adverse effects
Open accessThe DOI matches its Crossref record; 658 of the 659 references it cites were found in a registry or an index.
Abstract
Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precipitous increase in novel and designer drugs (eg, cathinones, amphetamines) in the market complicates the clinical picture.3”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 658
Banister, S. D., & Connor, M. A. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_143 · Cited by 105
Rickli, A., Liakoni, E., Hoener, M. C., & Liechti, M. E. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14105 · Cited by 104
Self-citationGHB receptor targets in the CNS: Focus on high-affinity binding sites
Bay, T., Eghorn, L. F., Klein, A. B., & Wellendorph, P. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.028 · Cited by 103
Deutsch, H. M., Shi, Q., Gruszecka‐Kowalik, E., & Schweri, M. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950697c · Cited by 103
A case of U-47700 overdose with laboratory confirmation and metabolite identification
Jones, M., Hernandez, B. S., Janis, G. C., & Stellpflug, S. J. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1209767 · Cited by 103
Prevalence of use and acute toxicity associated with the use of NBOMe drugs
Wood, D. M., Sedefov, R., Cunningham, A., & Dargan, P. I. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1004179 · Cited by 102
Schep, L. J., Slaughter, R. J., Hudson, S. C., Place, R., & Watts, M. (2014) · Human & Experimental Toxicology · doi:10.1177/0960327114550886 · Cited by 102
Rahnema, C. D., Crosnoe, L. E., & Kim, E. D. (2015) · Andrology · doi:10.1111/andr.307 · Cited by 101
Synthetic Cannabinoid Exposures Reported to Texas Poison Centers
Forrester, M. B., Kleinschmidt, K., Schwarz, E. S., & Young, A. (2011) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.609807 · Cited by 101
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101
Reinforcing and subjective effects of several anorectics in normal human volunteers.
Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39173-1 · Cited by 101
Butyrfentanyl Overdose Resulting in Diffuse Alveolar Hemorrhage
Cole, J. B., Dunbar, J. F., McIntire, S., Regelmann, W. E., & Slusher, T. M. (2015) · PEDIATRICS · doi:10.1542/peds.2014-2878 · Cited by 100
Two cases of intoxication with new synthetic opioid, U-47700
Domanski, K., Kleinschmidt, K., Schulte, J., Fleming, S. W., Frazee, C. C., Menendez, A., & Tavakoli, K. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1209763 · Cited by 100
Fatal Intoxication with α‐ PVP , a Synthetic Cathinone Derivative
Potocka‐Banaś, B., Janus, T., Majdanik, S., Banaś, T., Dembińska, T., & Borowiak, K. S. (2016) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13326 · Cited by 100
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
Halberstadt, A. L. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_64 · Cited by 100
Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA
Angerer, V., Jacobi, S., Franz, F., Auwärter, V., & Pietsch, J. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.10.042 · Cited by 100
Every‐Palmer, S. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03119.x · Cited by 99
A Gut Gone to Pot: A Case of Cannabinoid Hyperemesis Syndrome due to K2, a Synthetic Cannabinoid
Ukaigwe, A. C., Karmacharya, P., & Donato, A. A. (2014) · Case Reports in Emergency Medicine · doi:10.1155/2014/167098 · Cited by 99
Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99
Corkery, J. M., Loi, B., Claridge, H., Goodair, C., Corazza, O., Elliott, S., & Schifano, F. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.012 · Cited by 98
Strokes are possible complications of cannabinoids use
Wolff, V., & Jouanjus, É. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.01.031 · Cited by 98
Helander, A., Bäckberg, M., Signell, P., & Beck, O. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1303141 · Cited by 98
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 97
Mills, E., Rusyniak, D. E., & Sprague, J. E. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0591-7 · Cited by 97
Nagai, H., Saka, K., Nakajima, M., Maeda, H., Kuroda, R., Igarashi, A., Tsujimura-Ito, T., Nara, A., Komori, M., & Yoshida, K.-I. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.262 · Cited by 97
Di Cara, B., Maggio, R., Aloisi, G., Rivet, J.-M., Lundius, E. G., Yoshitake, T., Svenningsson, P., Brocco, M., Gobert, A., De Groote, L., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2502-11.2011 · Cited by 97
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids
Hopkins, C. Y., & Gilchrist, B. L. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.11.034 · Cited by 97
Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class
Schneir, A., Metushi, I. G., Sloane, C., Benaron, D. J., & Fitzgerald, R. L. (2017) · Clinical Toxicology · doi:10.1080/15563650.2016.1209764 · Cited by 97
Gamage, T. F., Farquhar, C. E., Lefever, T. W., Marusich, J. A., Kevin, R. C., McGregor, I. S., Wiley, J. L., & Thomas, B. F. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246983 · Cited by 97
An Outbreak of Synthetic Cannabinoid–Associated Coagulopathy in Illinois
Kelkar, A. H., Smith, N. A., Martial, A. M., Moole, H. V., Tarantino, M. D., & Roberts, J. C. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807652 · Cited by 97
K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
Patton, A. L., Chimalakonda, K. C., Moran, C. L., McCain, K. R., Radominska‐Pandya, A., James, L. P., Kokes, C., & Moran, J. H. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12216 · Cited by 96
Acute renal failure after ecstasy.
Fahal, I. H., Sallomi, D., Yaqoob, M., & Bell, G. M. (1992) · BMJ · doi:10.1136/bmj.305.6844.29 · Cited by 96
Vorce, S. P., Knittel, J. L., Holler, J. M., Magluilo, J., LEVINE, B. S., Berran, P. J., & Bosy, T. Z. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku011 · Cited by 96
Fatal intoxication with synthetic cannabinoid MDMB-CHMICA
Adamowicz, P. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.02.024 · Cited by 95
Sofalvi, S., Schueler, H. E., Lavins, E. S., Naso-Kaspar, C. K., Brooker, I. T., Mazzola, C. D., Dolinak, D., Gilson, T. P., & Perch, S. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx052 · Cited by 95
Tang, M. H. Y., Ching, C. K., Tsui, M. S. H., Chu, F. K. C., & Mak, T. W. L. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.909932 · Cited by 94
Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats
Paydar, M. J., Nguyen, J. D., Vandewater, S. A., Dickerson, T. J., & Taffe, M. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.002 · Cited by 94
Schwartz, M. D., Trecki, J., Edison, L., Steck, A., Arnold, J. K., & Gerona, R. R. L. (2015) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2014.12.038 · Cited by 92
Misuse of benzodiazepines and Z-drugs in the UK
Kapil, V., Green, J. L., Lait, C. L., Wood, D. M., & Dargan, P. I. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.149252 · Cited by 92
An Accidental Fatal Intoxication with Methoxetamine
Wikström, M., Thelander, G., Dahlgren, M., & Kronstrand, R. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bks086 · Cited by 92
Baumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang, X. P., Xu, J., Roth, B. L., Pan, Y.-X., & Pasternak, G. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.016 · Cited by 92
Blicke, F. F., & Burckhalter, J. H. (1942) · Journal of the American Chemical Society · doi:10.1021/ja01255a001 · Cited by 92
Stellpflug, S. J., Kealey, S. E., Hegarty, C. B., & Janis, G. C. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0314-y · Cited by 91
Foxy methoxy: A new drug of abuse
Smolinske, S. C., Rastogi, R., & Schenkel, S. M. (2005) · Journal of Medical Toxicology · doi:10.1007/bf03160901 · Cited by 91
Two fatalities associated with synthetic opioids: AH-7921 and MT-45
Fels, H., Krueger, J., Sachs, H., Mußhoff, F., Graw, M., Roider, G., & Stöver, A. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.04.003 · Cited by 91
Designer Benzodiazepines: Another Class of New Psychoactive Substances
Moosmann, B., & Auwärter, V. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_154 · Cited by 91
Death following ingestion of methylone
Barrios, L., Grison-Hernando, H., Boels, D., Bouquié, R., Monteil‐Ganière, C., & Clément, R. (2015) · International Journal of Legal Medicine · doi:10.1007/s00414-015-1212-4 · Cited by 90
Hasegawa, K., Wurita, A., Minakata, K., Gonmori, K., Yamagishi, I., Nozawa, H., Watanabe, K., & Suzuki, O. (2014) · Forensic Toxicology · doi:10.1007/s11419-014-0259-0 · Cited by 90
Acute intoxication by synthetic cannabinoids – Four case reports
Hermanns‐Clausen, M., Kneisel, S., Hutter, M., Szabó, B., & Auwärter, V. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1483 · Cited by 90
Sex Differences in the Effects of MDMA (Ecstasy) on Plasma Copeptin in Healthy Subjects
Simmler, L. D., Hysek, C. M., & Liechti, M. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1143 · Cited by 90
Self-citationAn outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA
Tyndall, J. A., Gerona, R. R. L., Portu, G. D., Trecki, J., Elie-Turenne, M.-C., Lucas, J. K., Slish, J. H., Rand, K. H., Bazydlo, L. A. L., Holder, M. C., et al. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1100306 · Cited by 90
Amoroso, T., & Workman, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116642542 · Cited by 90
Synthetic Cannabis and Acute Ischemic Stroke
Bernson‐Leung, M. E., Leung, L. Y., & Kumar, S. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.07.030 · Cited by 89
Wilkins, C., Sweetsur, P., & Girling, M. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801956140 · Cited by 89
Treatment or “high”: Benzodiazepine use in patients on injectable heroin or oral opioids
Vogel, M., Knöpfli, B., Schmid, O., Prica, M., Strasser, J., Prieto, L. C. V., Wiesbeck, G. A., & Dürsteler‐MacFarland, K. M. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.05.008 · Cited by 88
Synthetic cannabinoid use associated with acute kidney injury*
Thornton, S. L., Wood, C., Friesen, M. W., & Gerona, R. R. L. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.770870 · Cited by 88
Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”)
Greene, S. L., Dargan, P. I., O’Connor, N., Jones, A. L., & Kerins, M. (2003) · The American Journal of Emergency Medicine · doi:10.1053/ajem.2003.50028 · Cited by 88
Acute Chlorophenylpiperazine Overdose: A Case Report and Review of the Literature
Kovaleva, J., Devuyst, E., Paepe, P. D., & Verstraete, A. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318170a879 · Cited by 88
Characteristics and circumstances of synthetic cannabinoid-related death
Darke, S. G., Duflou, J. A., Farrell, M., Peacock, A., & Lappin, J. (2019) · Clinical Toxicology · doi:10.1080/15563650.2019.1647344 · Cited by 88
A fatal case of MAM-2201 poisoning
Saito, T., Namera, A., Miura, N., Ohta, S., Miyazaki, S., Osawa, M., & Inokuchi, S. (2013) · Forensic Toxicology · doi:10.1007/s11419-013-0190-9 · Cited by 87
Monte, A. P., Marona‐Lewicka, D., Cozzi, N. V., & Nichols, D. E. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00075a027 · Cited by 87
Ketamine-like Effects After Recreational Use of Methoxetamine
Hofer, K. E., Grager, B., Müller, D. M., Rauber‐Lüthy, C., Kupferschmidt, H., Rentsch, K., & Ceschi, A. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.11.018 · Cited by 87
Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine
Helander, A., Beck, O., & Bäckberg, M. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1033630 · Cited by 87
Bäckberg, M., Lindeman, E., Beck, O., & Helander, A. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.981823 · Cited by 86
Case Series of Synthetic Cannabinoid Intoxication from One Toxicology Center
Katz, K. D., Leonetti, A., Bailey, B., Surmaitis, R. M., Eustice, E., Kacinko, S. L., & Wheatley, S. M. (2016) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2016.2.29519 · Cited by 86
Wood, D. M., Brailsford, A. D., & Dargan, P. I. (2011) · Drug Testing and Analysis · doi:10.1002/dta.292 · Cited by 85
Carpenter, J. E., Murray, B. P., Dunkley, C. A., Kazzi, Z., & Gittinger, M. H. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1510502 · Cited by 85
Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation
Shields, J. E., Dargan, P. I., Wood, D. M., Puchnarewicz, M., Davies, S., & Waring, W. S. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.683437 · Cited by 84
An autopsy case of acetyl fentanyl intoxication caused by insufflation of ‘designer drugs’
Takase, I., Koizumi, T., Fujimoto, I., Yanai, A., & Fujimiya, T. (2016) · Legal Medicine · doi:10.1016/j.legalmed.2016.05.006 · Cited by 84
Kusano, M., Zaitsu, K., Taki, K., Hisatsune, K., Nakajima, J., Moriyasu, T., Asano, T., Hayashi, Y., Tsuchihashi, H., & Ishii, A. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2215 · Cited by 84
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., Wallach, J. V., & Halberstadt, A. L. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1884 · Cited by 84
McQuade, D., Hudson, S. C., Dargan, P. I., & Wood, D. M. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1379-2 · Cited by 83
A Unique Case of Cardiac Arrest following K2 Abuse
Ibrahim, S., Al-Saffar, F. I., & Wannenburg, T. (2014) · Case Reports in Cardiology · doi:10.1155/2014/120607 · Cited by 83
A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid
Takematsu, M., Hoffman, R. S., Nelson, L. S., Schechter, J., Moran, J. H., & Wiener, S. W. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.958614 · Cited by 83
The Paradox of 5-Methoxy-N,N-Dimethyltryptamine
Winter, J. C., Filipink, R. A., Timineri, D. M., Helsley, S., & Rabin, R. A. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00178-1 · Cited by 83
Poklis, J. L., Nanco, C. R., Troendle, M. M., Wolf, C. E., & Poklis, A. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1522 · Cited by 82
Excited delirium following use of synthetic cathinones (bath salts)
Penders, T. M., Gestring, R. E., & Vilensky, D. A. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.06.005 · Cited by 82
Valente, M. J., Bastos, M. D. L., Fernandes, E. G. R., Carvalho, F. D., de Pinho, P. G., & Carvalho, M. C. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00421 · Cited by 82
25I-NBOMe related death in Australia: A case report
Kueppers, V. B., & Cooke, C. T. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.02.010 · Cited by 81
Fatality Due to Acute α-Methyltryptamine Intoxication
Boland, D. M., Andollo, W., Hime, G. W., & Hearn, W. L. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.5.394 · Cited by 81
Counterfeiting in performance‐ and image‐enhancing drugs
Graham, M. R., Ryan, P., Baker, J. S., Davies, B., Thomas, N. E., Cooper, S., Evans, P. J., Easmon, S., Walker, C. J., Cowan, D., et al. (2009) · Drug Testing and Analysis · doi:10.1002/dta.30 · Cited by 80
Delirium Due to Intoxication from the Novel Synthetic Tryptamine 5‐MeO‐ DALT
Jovel, A., Felthous, A. R., & Bhattacharyya, A. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12367 · Cited by 80
Volz, T. J., Hanson, G. R., & Fleckenstein, A. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04419.x · Cited by 79
Lethal poisonings with AH-7921 in combination with other substances
Karinen, R., Tuv, S. S., Rogde, S., Peres, M. D., Johansen, U., Frost, J., Vindenes, V., & Øiestad, Å. M. L. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.08.013 · Cited by 79
Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project
Bäckberg, M., Tworek, L., Beck, O., & Helander, A. (2016) · Journal of Medical Toxicology · doi:10.1007/s13181-016-0584-2 · Cited by 79
Psychosis and synthetic cannabinoids
Deng, H., Verrico, C. D., Kosten, T. R., & Nielsen, D. A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.012 · Cited by 79
Eshleman, A. J., Wolfrum, K. M., Reed, J. F., Kim, S. O., Johnson, R. A., & Janowsky, A. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.024 · Cited by 79
Fantegrossi, W. E., Reissig, C. J., KATZ, E., Yarosh, H. L., Rice, K. C., & WINTER, J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.007 · Cited by 78
Bäckberg, M., Beck, O., & Helander, A. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1079325 · Cited by 78
Coopman, V., Blanckaert, P., Parys, G. V., Calenbergh, S. V., & Cordonnier, J. A. C. M. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.05.001 · Cited by 78
Helander, A., Bradley, M., Hasselblad, A., Norlén, L., Vassilaki, I., Bäckberg, M., & Lapins, J. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15174 · Cited by 78
Fatal Intoxications Associated with the Designer Opioid AH-7921
Kronstrand, R., Thelander, G., Lindstedt, D., Roman, M., & Kugelberg, F. C. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku057 · Cited by 77
Patterns of Ecstasy-Associated Hyponatremia in California
Rosenson, J., Smollin, C. G., Sporer, K. A., Blanc, P. D., & Olson, K. R. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.09.018 · Cited by 77
Foxy, a Designer Tryptamine Hallucinogen*
Meatherall, R., & Sharma, P. (2003) · Journal of Analytical Toxicology · doi:10.1093/jat/27.5.313 · Cited by 77
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats
Fantegrossi, W. E., Harrington, A. W., Eckler, J. R., Arshad, S., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0009-4 · Cited by 77
Review of the many faces of synthetic cannabinoid toxicities
Alipour, A., Patel, P. B., Shabbir, Z., & Gabrielson, S. W. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.03.093 · Cited by 77
Pathological Findings in 2 Cases of Fatal 25I-NBOMe Toxicity
Walterscheid, J. P., Phillips, G. T., Lopez, A. E., Gonsoulin, M. L., Chen, H.-H., & Sanchez, L. A. (2014) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000082 · Cited by 76
Forsling, M. L., Fallon, J. K., Shah, D., Tilbrook, G. S., Cowan, D. A., Kicman, A. T., & Hutt, A. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704502 · Cited by 76
Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014
Shanks, K. G., Sozio, T. J., & Behonick, G. S. (2015) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv058 · Cited by 76
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., Lodge, D., Halberstadt, A. L., Brandt, S. D., & Adejare, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157021 · Cited by 76
The Xyrem?? Risk Management Program
Fuller, D. E., Hornfeldt, C. S., Kelloway, J. S., Stahl, P. J., & Anderson, T. F. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00002 · Cited by 75
Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin
Balmelli, C., Kupferschmidt, H., Rentsch, K. M., & Schneemann, M. (2001) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2001-15702 · Cited by 75
Mayer, F. P., Wimmer, L., Dillon‐Carter, O., Partilla, J. S., Burchardt, N., Mihovilovič, M. D., Baumann, M. H., & Sitte, H. H. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13547 · Cited by 74
Rothman, R. B., Katsnelson, M., Vu, N., Partilla, J. S., Dersch, C. M., Blough, B. E., & Baumann, M. H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01830-7 · Cited by 73
Jensen, A. A., McCorvy, J. D., Leth‐Petersen, S., Bundgaard, C., Liebscher, G., Kenakin, T., Bräuner‐Osborne, H., Kehler, J., & Kristensen, J. L. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.239905 · Cited by 73
Miliano, C., Margiani, G., Fattore, L., & Luca, M. A. D. (2018) · Brain Sciences · doi:10.3390/brainsci8070123 · Cited by 73
Wood, D. M., Button, J., Lidder, S., Ramsey, J. M., Holt, D. W., & Dargan, P. I. (2008) · Journal of Medical Toxicology · doi:10.1007/bf03161209 · Cited by 72
Aminoindanes—the next wave of ‘legal highs’?
Sainsbury, P. D., Kicman, A. T., Archer, R., King, L. A., & Braithwaite, R. A. (2011) · Drug Testing and Analysis · doi:10.1002/dta.318 · Cited by 72
McKeever, R., Vearrier, D., Jacobs, D., LaSala, G. S., Okaneku, J., & Greenberg, M. I. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-014-0424-1 · Cited by 72
Eshleman, A. J., Forster, M. J., Wolfrum, K. M., Johnson, R. A., Janowsky, A., & Gatch, M. B. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3303-6 · Cited by 72
Effects ofp-chloroamphetamine on brain serotonin neurons
Fuller, R. W. (1992) · Neurochemical Research · doi:10.1007/bf00969891 · Cited by 72
5-Methoxy-N,N-Diisopropyltryptamine-Induced Flashbacks
Akifumi, I., SEKIGUCHI, K., Fujita, K.-I., Yamadera, H., & Koga, Y. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.815 · Cited by 72
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., Wallach, J. V., & Halberstadt, A. L. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2613 · Cited by 72
Seizures and Hyponatremia Related to Ethcathinone and Methylone Poisoning
Boulanger-Gobeil, C., St-Onge, M., Laliberté, M., & Auger, P. L. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0159-1 · Cited by 71
Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
Martinotti, G., Santacroce, R., Papanti, D., Elgharably, Y., Prilutskaya, M., & Corazza, O. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170413101839 · Cited by 71
Luethi, D., & Liechti, M. E. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy047 · Cited by 71
Self-citationFinlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., Banister, S. D., & Glass, M. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00429 · Cited by 71
Valente, M. J., Araújo, A. M., Silva, R., Bastos, M. D. L., Carvalho, F. D., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1653-z · Cited by 70
Staeheli, S. N., Baumgartner, M. R., Gauthier, S., Gascho, D., Jarmer, J., Kræmer, T., & Steuer, A. E. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.05.034 · Cited by 70
Intoxications involving MDPV in Sweden during 2010–2014: Results from the STRIDA project
Beck, O., Franzén, L., Bäckberg, M., Signell, P., & Helander, A. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1089576 · Cited by 69
A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration Distribution
McIntyre, I. M., Gary, R. D., Joseph, S., & Stabley, R. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw124 · Cited by 69
Toxicity from the recreational use of 1-benzylpiperazine
Gee, P., Gilbert, M. J., Richardson, S. K., Moore, G., Paterson, S., & Graham, P. J. (2008) · Clinical Toxicology · doi:10.1080/15563650802307602 · Cited by 68
Curtis, B., Kemp, P. M., Harty, L., Choi, C., & Christensen, D. (2003) · Journal of Analytical Toxicology · doi:10.1093/jat/27.7.493 · Cited by 68
Ocfentanil overdose fatality in the recreational drug scene
Coopman, V., Cordonnier, J. A. C. M., Leeuw, M. D., & Cirimele, V. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.07.005 · Cited by 68
Valente, M. J., Amaral, C., Correia‐da‐Silva, G., Duarte, J. A., Bastos, M. D. L., Carvalho, F. D., de Pinho, P. G., & Carvalho, M. C. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1984-z · Cited by 68
Synthetic cannabinoid induced acute respiratory depression: Case series and literature review
Alon, M. H., & Saint-Fleur, M. O. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.07.011 · Cited by 68
Armenian, P., Darracq, M. A., Gevorkyan, J., Clark, S., Kaye, B., & Brandehoff, N. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.017 · Cited by 67
Brennan, R., & Van Hout, M. C. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.921746 · Cited by 66
Synthetic Cannabinoids and Acute Kidney Injury
Srisung, W., Jamal, F., & Prabhakar, S. S. (2015) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2015.11929313 · Cited by 66
Mephedrone related fatalities: a review.
Busardò, F. P., Kyriakou, C., Napoletano, S., Marinelli, E., & Zaami, S. (2015) · PubMed · Cited by 65
Spice: A Legal Marijuana Equivalent
Johnson, L. A., Johnson, R. L., & Alfonzo, C. (2011) · Military Medicine · doi:10.7205/milmed-d-10-00356 · Cited by 65
Psychiatric Sequelae of Spice, K2, and Synthetic Cannabinoid Receptor Agonists
Benford, D. M., & Caplan, J. P. (2011) · Psychosomatics · doi:10.1016/j.psym.2011.01.004 · Cited by 65
Mathur, D., María-Lafuente, E., Ureña-Peralta, J., Sorribes, L., Hernández, A., Casanova, B., López-Rodas, G., Coret-Ferrer, F., & Burgal-Marti, M. (2017) · Brain Sciences · doi:10.3390/brainsci8010001 · Cited by 65
Brandt, S. D., Kavanagh, P. V., Westphal, F., Elliott, S. P., Wallach, J., Colestock, T., Burrow, T. E., Chapman, S. J., Stratford, A., Nichols, D. E., et al. (2017) · Drug Testing and Analysis · doi:10.1002/dta.1985 · Cited by 64
Beck, O., Franzén, L., Bäckberg, M., Signell, P., & Helander, A. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1190979 · Cited by 64
Pharmacological profile of methylphenidate-based designer drugs
Luethi, D., Kaeser, P. J., Brandt, S. D., Krähenbühl, S., Hoener, M. C., & Liechti, M. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.020 · Cited by 64
Self-citationCarter, L. P., Chen, W., Wu, H., Mehta, A. K., Hernandez, R. J., Ticku, M. K., Coop, A., Koek, W., & France, C. P. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.10.002 · Cited by 63
mCPP: an undesired addition to the ecstasy market
Bossong, M. G., Brunt, T. M., Dijk, J. V., Rigter, S., Hoek, J., Goldschmidt, H. M. J., & Niesink, R. J. M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102541 · Cited by 63
Bäckberg, M., Bergstrand, M. P., Beck, O., & Helander, A. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1506130 · Cited by 63
Synthetic marijuana and acute kidney injury: an unforeseen association
Kazory, A., & Aiyer, R. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sft047 · Cited by 62
Novel Synthetic Opioids: An Opioid Epidemic Within an Opioid Epidemic
Lucyk, S. N., & Nelson, L. S. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.08.445 · Cited by 62
Alhadi, S., Tiwari, A., Vohra, R. B., Gerona, R. R. L., Acharya, J., & Bilello, K. L. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0288-9 · Cited by 61
Gugelmann, H., Gerona, R., Li, C., Tsutaoka, B., Olson, K. R., & Lung, D. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.925562 · Cited by 61
Legal piperazine‐containing party pills‐a new trend in substance misuse
Sheridan, J. L., Butler, R., Wilkins, C., & Russell, B. (2007) · Drug and Alcohol Review · doi:10.1080/09595230701255791 · Cited by 61
Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Carvalho, M., Pontes, H., Remiao, F., L. Bastos, M., & Carvalho, F. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110791591535 · Cited by 61
Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB)
Adamowicz, P., Zuba, D., & Byrska, B. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.10.016 · Cited by 61
Internet Highs—Seizures After Consumption of Synthetic Cannabinoids Purchased Online
Tofighi, B., & Lee, J. D. (2012) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182619004 · Cited by 61
Yonemitsu, K., Sasao, A., Mishima, S., Ohtsu, Y., & Nishitani, Y. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.08.025 · Cited by 61
Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones
Luethi, D., Liechti, M. E., & Krähenbühl, S. (2017) · Toxicology · doi:10.1016/j.tox.2017.06.004 · Cited by 61
Self-citationWhat are the psychological effects of using synthetic cannabinoids? A systematic review
Akram, H., Mokrysz, C., & Curran, H. V. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119826592 · Cited by 61
Kudo, K., Usumoto, Y., Kikura‐Hanajiri, R., Sameshima, N., Tsuji, A., & Ikeda, N. (2015) · Legal Medicine · doi:10.1016/j.legalmed.2015.06.005 · Cited by 60
Acute confusional state after designer tryptamine abuse
Itokawa, M., Iwata, K., Takahashi, M., SUGIHARA, G., Sasaki, T., ABE, Y., UNO, M., Hobo, M., Jitoku, D., INOUE, K., et al. (2007) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01638.x · Cited by 60
Synthetic Androgens as Designer Supplements
Joseph, J., & Parr, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210224756 · Cited by 60
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J. V., Stratford, A., Klein, L. M., McCorvy, J. D., Nichols, D. E., et al. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2222 · Cited by 60
Partridge, E., Trobbiani, S., Stockham, P. C., Charlwood, C., & Kostakis, C. (2018) · Journal of Analytical Toxicology · doi:10.1093/jat/bky039 · Cited by 60
In vitro determination of the efficacy of illicit synthetic cannabinoids at CB 1 receptors
Sachdev, S., Vemuri, K. V., Banister, S. D., Longworth, M., Kassiou, M., Santiago, M., Makriyannis, A., & Connor, M. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14829 · Cited by 60
Dawson, P., Opacka‐Juffry, J., Moffatt, J. D., Daniju, Y., Dutta, N., Ramsey, J., & Davidson, C. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.013 · Cited by 59
History and Pharmacology of PCP and PCP-Related Analogs
Domino, E. F. (1980) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1980.10471430 · Cited by 59
Persistent psychosis following the use of Spice
Veer, N. V. D., & Friday, J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.022 · Cited by 59
Recurrent Seizures and Serotonin Syndrome Following “2C-I” Ingestion
Bosak, A. R., LoVecchio, F., & Levine, M. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0287-x · Cited by 58
First Reported Fatalities Associated with the 'Research Chemical' 2-Methoxydiphenidine
Elliott, S. P., Brandt, S. D., Wallach, J. V., Morris, H., & Kavanagh, P. V. (2015) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv006 · Cited by 58
Owen, D. R., Wood, D. M., Archer, J. R. H., & Dargan, P. I. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12356 · Cited by 58
Wiley, J. L., Lefever, T. W., Marusich, J. A., Grabenauer, M., Moore, K. N., Huffman, J. W., & Thomas, B. F. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.016 · Cited by 58
Fatality Following Ingestion of Tetrahydrofuranylfentanyl, U-49900 and Methoxy-Phencyclidine
Krotulski, A. J., Papsun, D. M., Friscia, M., Swartz, J. L., Holsey, B. D., & Logan, B. K. (2018) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx092 · Cited by 58
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.033 · Cited by 58
Wagmann, L., Richter, L. H. J., Kehl, T., Wack, F., Bergstrand, M. P., Brandt, S. D., Stratford, A., Maurer, H. H., & Meyer, M. R. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1558-9 · Cited by 58
Hemorrhagic stroke following use of the synthetic marijuana “spice”
Rose, D. Z., Guerrero, W. R., Mokin, M. V., Gooch, C. L., Bozeman, A. C., Pearson, J. M., & Burgin, W. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001973 · Cited by 57
Halberstadt, A. L., Nichols, D. E., & Geyer, M. A. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2616-6 · Cited by 57
Case reports of synthetic cannabinoid XLR-11 associated fatalities
Shanks, K. G., Winston, D., Heidingsfelder, J., & Behonick, G. S. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.04.021 · Cited by 57
Multiorgan failure from 1-benzylpiperazine ingestion – legal high or lethal high?
Gee, P., Jerram, T., & Bowie, D. (2010) · Clinical Toxicology · doi:10.3109/15563651003592948 · Cited by 57
Mitragynine concentrations in two fatalities
Domingo, O., Roider, G., Stöver, A., Graw, M., Mußhoff, F., Sachs, H., & Bicker, W. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.12.020 · Cited by 57
Longworth, M., Connor, M. A., Banister, S. D., & Kassiou, M. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00116 · Cited by 57
Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00617 · Cited by 57
Self-citationSelf-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys
Wee, S., & Woolverton, W. L. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.022 · Cited by 56
Methoxetamine – a novel recreational drug with potent hallucinogenic properties
Zawilska, J. B. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.08.011 · Cited by 56
Bingham, C. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.10.2654 · Cited by 56
Altıntaş, M., İnanç, L., Oruç, G. A., Arpacıoğlu, S., & Güleç, H. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s107622 · Cited by 56
Banister, S. D., Adams, A. J., Kevin, R. C., Macdonald, C. E., Glass, M., Boyd, R. A., Connor, M. A., McGregor, I. S., Havel, C. M., Bright, S. J., et al. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2491 · Cited by 56
Intravenous self-administration of entactogen-class stimulants in male rats
Vandewater, S. A., Creehan, K. M., & Taffe, M. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.030 · Cited by 55
Valente, M. J., Araújo, A. M., Bastos, M. D. L., Fernandes, E. G. R., Carvalho, F. D., de Pinho, P. G., & Carvalho, M. C. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw105 · Cited by 55
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.012 · Cited by 55
Self-citationAcetyl Fentanyl Toxicity: Two Case Reports
Fort, C., Curtis, B., Nichols, C., & Niblo, C. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw068 · Cited by 54
An Acute Ocfentanil Fatality: A Case Report with Postmortem Concentrations
Dussy, F. E., Hangartner, S., Hamberg, C., Berchtold, C., Scherer, U., Schlotterbeck, G., Wyler, D., & Briellmann, T. A. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw096 · Cited by 54
Waters, L. J., Manchester, K. R., Maskell, P., Haegeman, C., & Haider, S. M. (2017) · Science & Justice · doi:10.1016/j.scijus.2017.12.004 · Cited by 54
An Epidemic of Illicit Fentanyl Deaths in Cook County, Illinois: September 2005 through April 2007
Denton, J. S., Donoghue, E. R., McReynolds, J., & Kalelkar, M. B. (2008) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2008.00669.x · Cited by 53
Methoxetamine: a novel ketamine analog and growing health-care concern
Ward, J. A., Rhyee, S. H., Plansky, J., & Boyer, E. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.617310 · Cited by 53
Action of MDMA (Ecstasy) and Its Metabolites on Arginine Vasopressin Release
FALLON, J. K., SHAH, D., KICMAN, A. T., HUTT, A. J., HENRY, J. A., COWAN, D. A., & FORSLING, M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04181.x · Cited by 53
Fatality Involving the Ingestion of Phenazepam and Poppy Seed Tea
Bailey, K., Richards‐Waugh, L. L., Clay, D., Gebhardt, M. A., Mahmoud, H., & Kraner, J. C. (2010) · Journal of Analytical Toxicology · doi:10.1093/jat/34.8.527 · Cited by 53
Deaths Involving Methylenedioxypyrovalerone ( MDPV ) in Upper E ast T ennessee
Wright, T. H., Cline‐Parhamovich, K., Lajoie, D., Parsons, L., Dunn, M., & Ferslew, K. E. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12260 · Cited by 53
Gannon, B. M., Galindo, K. I., Mesmin, M. P., Sulima, A., Rice, K. C., & Collins, G. T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.018 · Cited by 53
Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: A case report
Martucci, H. F. H., Ingle, E. A., Hunter, M. D., & Rodda, L. N. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.12.005 · Cited by 53
Corkery, J., Elliott, S. P., Schifano, F., Corazza, O., & Ghodse, A. H. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2298 · Cited by 52
Synthetic Cannabinoid-Induced Psychosis: Two Adolescent Cases
Oluwabusi, O. O., Lobach, L., Akhtar, U., Youngman, B., & Ambrosini, P. J. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0004 · Cited by 52
Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border
Weber, C., Krug, O., Kamber, M., & Thevis, M. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2016.1263665 · Cited by 52
Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA
Adamowicz, P., Meissner, E., & Maślanka, M. (2019) · Clinical Toxicology · doi:10.1080/15563650.2019.1580371 · Cited by 52
Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use: A Case Report
Durand, D., Delgado, L. L., de la Parra-Pellot, D. M., & Nichols‐Vinueza, D. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.dude.031513 · Cited by 51
Teens and Spice: A Review of Adolescent Fatalities Associated with Synthetic Cannabinoid Use
Paul, A. B. M., Simms, L., Amini, S., & Paul, A. E. (2018) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13704 · Cited by 51
Richeval, C., Gaulier, J., Romeuf, L., Allorge, D., & Gaillard, Y. (2018) · International Journal of Legal Medicine · doi:10.1007/s00414-018-1969-3 · Cited by 51
Methoxetamine‐related deaths in the UK: an overview
Chiappini, S., Claridge, H., Corkery, J. M., Goodair, C., Loi, B., & Schifano, F. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2422 · Cited by 50
Teenage Cardiac Arrest Following Abuse of Synthetic Cannabis
Davis, C., & Boddington, D. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.04.176 · Cited by 50
Research works printed but not linked: 5
- Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
- Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
- Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
- Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
- Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Anghel, D.-M. C., Nițescu, G. V., Tiron, A. T., Guțu, C. M., & Baconi, D. L. (2023) · Molecules · doi:10.3390/molecules28134969 · Cited by 124
A review of synthetic cathinones emerging in recent years (2019–2022)
Kuropka, P., Zawadzki, M., & Szpot, P. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00639-5 · Cited by 79
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 68
Metadata
- Authors
- Luethi, D., & Liechti, M. E.
- Affiliations
- TU Wien (AT)
- University of Basel (CH)
- Corresponding author
- Luethi, Dino
- Venue
- Archives of Toxicology
- Published
- 2020-04
- Volume
- 94
- Issue
- 4
- Pages
- 1085-1133
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC7225206
- OpenAlex
- W3014121938
- Cited by
- 262
- References
- 659
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 43 · 2023: 42 · 2022: 55 · 2021: 35 · 2020: 13
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-03-03)
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 5 d)
- Locations
- Archives of Toxicology (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_181809)
- Bundesamt für Gesundheit (16.921318)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- new psychoactive substances, mechanism of action, adverse drug reactions, stimulants, cathinone, monoamine transporters, sympathomimetic effects, sedatives, mu-opioid receptor agonism, GABA receptors, cardiorespiratory depression, dissociative drugs, NMDA receptor antagonists, ketamine, synthetic cannabinoids, CB1 receptor, serotonergic psychedelics, 5-HT2A receptor, drug screening, polydrug use
- MeSH terms
- Central Nervous System Stimulants, Cannabinoids, Hallucinogens, Humans, Psychotropic Drugs, Serotonin, Illicit Drugs, Designer Drugs, Molecular Structure, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.